nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—PTGS2—bone cancer	0.429	1	CbGaD
Nabumetone—MPO—Carboplatin—bone cancer	0.234	0.465	CbGbCtD
Nabumetone—MPO—Cisplatin—bone cancer	0.2	0.398	CbGbCtD
Nabumetone—PTGS2—Cisplatin—bone cancer	0.069	0.137	CbGbCtD
Nabumetone—MPO—Folate Metabolism—FOLR1—bone cancer	0.000552	0.156	CbGpPWpGaD
Nabumetone—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.000387	0.109	CbGpPWpGaD
Nabumetone—Abnormal vision—Epirubicin—bone cancer	0.000302	0.00467	CcSEcCtD
Nabumetone—Aplastic anaemia—Doxorubicin—bone cancer	0.000301	0.00465	CcSEcCtD
Nabumetone—Alopecia—Cisplatin—bone cancer	0.000299	0.00462	CcSEcCtD
Nabumetone—Hepatic failure—Methotrexate—bone cancer	0.000299	0.00462	CcSEcCtD
Nabumetone—Flatulence—Cisplatin—bone cancer	0.000291	0.00449	CcSEcCtD
Nabumetone—Thrombophlebitis—Epirubicin—bone cancer	0.000291	0.00449	CcSEcCtD
Nabumetone—Photosensitivity—Epirubicin—bone cancer	0.000286	0.00442	CcSEcCtD
Nabumetone—Hepatic failure—Epirubicin—bone cancer	0.00028	0.00432	CcSEcCtD
Nabumetone—Abnormal vision—Doxorubicin—bone cancer	0.00028	0.00432	CcSEcCtD
Nabumetone—Anaphylactoid reaction—Methotrexate—bone cancer	0.000278	0.00429	CcSEcCtD
Nabumetone—Tremor—Cisplatin—bone cancer	0.000276	0.00427	CcSEcCtD
Nabumetone—Ill-defined disorder—Cisplatin—bone cancer	0.000274	0.00423	CcSEcCtD
Nabumetone—Anaemia—Cisplatin—bone cancer	0.000273	0.00421	CcSEcCtD
Nabumetone—Thrombophlebitis—Doxorubicin—bone cancer	0.000269	0.00415	CcSEcCtD
Nabumetone—Increased appetite—Epirubicin—bone cancer	0.000268	0.00413	CcSEcCtD
Nabumetone—Malaise—Cisplatin—bone cancer	0.000266	0.00411	CcSEcCtD
Nabumetone—Photosensitivity—Doxorubicin—bone cancer	0.000265	0.00409	CcSEcCtD
Nabumetone—Leukopenia—Cisplatin—bone cancer	0.000264	0.00408	CcSEcCtD
Nabumetone—Dermatitis bullous—Epirubicin—bone cancer	0.000263	0.00406	CcSEcCtD
Nabumetone—Anaphylactoid reaction—Epirubicin—bone cancer	0.00026	0.00401	CcSEcCtD
Nabumetone—Hepatic failure—Doxorubicin—bone cancer	0.000259	0.004	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000252	0.00388	CcSEcCtD
Nabumetone—Anxiety—Cisplatin—bone cancer	0.00025	0.00386	CcSEcCtD
Nabumetone—Liver function test abnormal—Methotrexate—bone cancer	0.000248	0.00383	CcSEcCtD
Nabumetone—Discomfort—Cisplatin—bone cancer	0.000248	0.00383	CcSEcCtD
Nabumetone—Increased appetite—Doxorubicin—bone cancer	0.000248	0.00382	CcSEcCtD
Nabumetone—Dermatitis bullous—Doxorubicin—bone cancer	0.000244	0.00376	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000242	0.00374	CcSEcCtD
Nabumetone—Anaphylactic shock—Cisplatin—bone cancer	0.000241	0.00372	CcSEcCtD
Nabumetone—Oedema—Cisplatin—bone cancer	0.000241	0.00372	CcSEcCtD
Nabumetone—Anaphylactoid reaction—Doxorubicin—bone cancer	0.00024	0.00371	CcSEcCtD
Nabumetone—Thrombocytopenia—Cisplatin—bone cancer	0.000236	0.00364	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000233	0.00359	CcSEcCtD
Nabumetone—Hyperhidrosis—Cisplatin—bone cancer	0.000233	0.00359	CcSEcCtD
Nabumetone—Asthma—Methotrexate—bone cancer	0.000232	0.00359	CcSEcCtD
Nabumetone—Liver function test abnormal—Epirubicin—bone cancer	0.000232	0.00359	CcSEcCtD
Nabumetone—Anorexia—Cisplatin—bone cancer	0.000229	0.00354	CcSEcCtD
Nabumetone—Hypokalaemia—Epirubicin—bone cancer	0.000229	0.00353	CcSEcCtD
Nabumetone—Pancreatitis—Methotrexate—bone cancer	0.000228	0.00352	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000227	0.0035	CcSEcCtD
Nabumetone—Gastritis—Epirubicin—bone cancer	0.000223	0.00344	CcSEcCtD
Nabumetone—Asthma—Epirubicin—bone cancer	0.000217	0.00336	CcSEcCtD
Nabumetone—Dysphagia—Epirubicin—bone cancer	0.000217	0.00336	CcSEcCtD
Nabumetone—Dysuria—Methotrexate—bone cancer	0.000217	0.00335	CcSEcCtD
Nabumetone—Paraesthesia—Cisplatin—bone cancer	0.000216	0.00334	CcSEcCtD
Nabumetone—Liver function test abnormal—Doxorubicin—bone cancer	0.000215	0.00332	CcSEcCtD
Nabumetone—Dyspnoea—Cisplatin—bone cancer	0.000215	0.00331	CcSEcCtD
Nabumetone—Erectile dysfunction—Methotrexate—bone cancer	0.000214	0.0033	CcSEcCtD
Nabumetone—Pancreatitis—Epirubicin—bone cancer	0.000213	0.00329	CcSEcCtD
Nabumetone—Photosensitivity reaction—Methotrexate—bone cancer	0.000212	0.00327	CcSEcCtD
Nabumetone—Hypokalaemia—Doxorubicin—bone cancer	0.000212	0.00327	CcSEcCtD
Nabumetone—Angina pectoris—Epirubicin—bone cancer	0.000212	0.00327	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00021	0.00324	CcSEcCtD
Nabumetone—Decreased appetite—Cisplatin—bone cancer	0.000209	0.00323	CcSEcCtD
Nabumetone—Pneumonia—Methotrexate—bone cancer	0.000208	0.00322	CcSEcCtD
Nabumetone—Depression—Methotrexate—bone cancer	0.000207	0.00319	CcSEcCtD
Nabumetone—Gastritis—Doxorubicin—bone cancer	0.000206	0.00318	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000205	0.00317	CcSEcCtD
Nabumetone—Renal failure—Methotrexate—bone cancer	0.000204	0.00314	CcSEcCtD
Nabumetone—Dysuria—Epirubicin—bone cancer	0.000203	0.00314	CcSEcCtD
Nabumetone—Stomatitis—Methotrexate—bone cancer	0.000202	0.00312	CcSEcCtD
Nabumetone—Dysphagia—Doxorubicin—bone cancer	0.000201	0.00311	CcSEcCtD
Nabumetone—Asthma—Doxorubicin—bone cancer	0.000201	0.00311	CcSEcCtD
Nabumetone—Photosensitivity reaction—Epirubicin—bone cancer	0.000198	0.00306	CcSEcCtD
Nabumetone—Feeling abnormal—Cisplatin—bone cancer	0.000198	0.00306	CcSEcCtD
Nabumetone—Weight increased—Epirubicin—bone cancer	0.000198	0.00305	CcSEcCtD
Nabumetone—Haematuria—Methotrexate—bone cancer	0.000198	0.00305	CcSEcCtD
Nabumetone—Pancreatitis—Doxorubicin—bone cancer	0.000197	0.00305	CcSEcCtD
Nabumetone—Weight decreased—Epirubicin—bone cancer	0.000197	0.00304	CcSEcCtD
Nabumetone—Hyperglycaemia—Epirubicin—bone cancer	0.000196	0.00303	CcSEcCtD
Nabumetone—Angina pectoris—Doxorubicin—bone cancer	0.000196	0.00303	CcSEcCtD
Nabumetone—Pneumonia—Epirubicin—bone cancer	0.000195	0.00301	CcSEcCtD
Nabumetone—Agranulocytosis—Methotrexate—bone cancer	0.000193	0.00298	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000192	0.00297	CcSEcCtD
Nabumetone—Renal failure—Epirubicin—bone cancer	0.000191	0.00294	CcSEcCtD
Nabumetone—Body temperature increased—Cisplatin—bone cancer	0.00019	0.00294	CcSEcCtD
Nabumetone—Jaundice—Epirubicin—bone cancer	0.000189	0.00292	CcSEcCtD
Nabumetone—Stomatitis—Epirubicin—bone cancer	0.000189	0.00292	CcSEcCtD
Nabumetone—Dysuria—Doxorubicin—bone cancer	0.000188	0.0029	CcSEcCtD
Nabumetone—Haemoglobin—Methotrexate—bone cancer	0.000187	0.00289	CcSEcCtD
Nabumetone—Haemorrhage—Methotrexate—bone cancer	0.000186	0.00287	CcSEcCtD
Nabumetone—Haematuria—Epirubicin—bone cancer	0.000185	0.00285	CcSEcCtD
Nabumetone—Photosensitivity reaction—Doxorubicin—bone cancer	0.000184	0.00284	CcSEcCtD
Nabumetone—Weight increased—Doxorubicin—bone cancer	0.000183	0.00283	CcSEcCtD
Nabumetone—Weight decreased—Doxorubicin—bone cancer	0.000182	0.00281	CcSEcCtD
Nabumetone—Hyperglycaemia—Doxorubicin—bone cancer	0.000181	0.0028	CcSEcCtD
Nabumetone—Agranulocytosis—Epirubicin—bone cancer	0.000181	0.00279	CcSEcCtD
Nabumetone—Pneumonia—Doxorubicin—bone cancer	0.00018	0.00279	CcSEcCtD
Nabumetone—Visual impairment—Methotrexate—bone cancer	0.000179	0.00277	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000178	0.00275	CcSEcCtD
Nabumetone—Hypersensitivity—Cisplatin—bone cancer	0.000177	0.00274	CcSEcCtD
Nabumetone—Renal failure—Doxorubicin—bone cancer	0.000176	0.00272	CcSEcCtD
Nabumetone—Erythema multiforme—Methotrexate—bone cancer	0.000176	0.00271	CcSEcCtD
Nabumetone—Haemoglobin—Epirubicin—bone cancer	0.000175	0.0027	CcSEcCtD
Nabumetone—Stomatitis—Doxorubicin—bone cancer	0.000175	0.0027	CcSEcCtD
Nabumetone—Jaundice—Doxorubicin—bone cancer	0.000175	0.0027	CcSEcCtD
Nabumetone—Haemorrhage—Epirubicin—bone cancer	0.000174	0.00269	CcSEcCtD
Nabumetone—Tinnitus—Methotrexate—bone cancer	0.000173	0.00268	CcSEcCtD
Nabumetone—Asthenia—Cisplatin—bone cancer	0.000173	0.00267	CcSEcCtD
Nabumetone—Haematuria—Doxorubicin—bone cancer	0.000171	0.00264	CcSEcCtD
Nabumetone—Visual impairment—Epirubicin—bone cancer	0.000168	0.00259	CcSEcCtD
Nabumetone—Agranulocytosis—Doxorubicin—bone cancer	0.000167	0.00258	CcSEcCtD
Nabumetone—Chills—Methotrexate—bone cancer	0.000167	0.00258	CcSEcCtD
Nabumetone—Diarrhoea—Cisplatin—bone cancer	0.000165	0.00254	CcSEcCtD
Nabumetone—Erythema multiforme—Epirubicin—bone cancer	0.000165	0.00254	CcSEcCtD
Nabumetone—Alopecia—Methotrexate—bone cancer	0.000164	0.00254	CcSEcCtD
Nabumetone—Tinnitus—Epirubicin—bone cancer	0.000162	0.00251	CcSEcCtD
Nabumetone—Haemoglobin—Doxorubicin—bone cancer	0.000162	0.0025	CcSEcCtD
Nabumetone—Haemorrhage—Doxorubicin—bone cancer	0.000161	0.00249	CcSEcCtD
Nabumetone—Chills—Epirubicin—bone cancer	0.000156	0.00241	CcSEcCtD
Nabumetone—Arrhythmia—Epirubicin—bone cancer	0.000155	0.0024	CcSEcCtD
Nabumetone—Visual impairment—Doxorubicin—bone cancer	0.000155	0.0024	CcSEcCtD
Nabumetone—Alopecia—Epirubicin—bone cancer	0.000154	0.00237	CcSEcCtD
Nabumetone—Vomiting—Cisplatin—bone cancer	0.000153	0.00236	CcSEcCtD
Nabumetone—Erythema multiforme—Doxorubicin—bone cancer	0.000152	0.00235	CcSEcCtD
Nabumetone—Rash—Cisplatin—bone cancer	0.000152	0.00234	CcSEcCtD
Nabumetone—Dermatitis—Cisplatin—bone cancer	0.000152	0.00234	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—DHFR—bone cancer	0.000151	0.0428	CbGpPWpGaD
Nabumetone—Ill-defined disorder—Methotrexate—bone cancer	0.00015	0.00232	CcSEcCtD
Nabumetone—Tinnitus—Doxorubicin—bone cancer	0.00015	0.00232	CcSEcCtD
Nabumetone—Anaemia—Methotrexate—bone cancer	0.00015	0.00231	CcSEcCtD
Nabumetone—Flatulence—Epirubicin—bone cancer	0.000149	0.0023	CcSEcCtD
Nabumetone—Tension—Epirubicin—bone cancer	0.000149	0.0023	CcSEcCtD
Nabumetone—Nervousness—Epirubicin—bone cancer	0.000147	0.00227	CcSEcCtD
Nabumetone—Malaise—Methotrexate—bone cancer	0.000146	0.00225	CcSEcCtD
Nabumetone—Vertigo—Methotrexate—bone cancer	0.000145	0.00225	CcSEcCtD
Nabumetone—Leukopenia—Methotrexate—bone cancer	0.000145	0.00224	CcSEcCtD
Nabumetone—Chills—Doxorubicin—bone cancer	0.000144	0.00223	CcSEcCtD
Nabumetone—Arrhythmia—Doxorubicin—bone cancer	0.000144	0.00222	CcSEcCtD
Nabumetone—Nausea—Cisplatin—bone cancer	0.000143	0.00221	CcSEcCtD
Nabumetone—Alopecia—Doxorubicin—bone cancer	0.000142	0.0022	CcSEcCtD
Nabumetone—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000142	0.0401	CbGpPWpGaD
Nabumetone—Cough—Methotrexate—bone cancer	0.000141	0.00218	CcSEcCtD
Nabumetone—Ill-defined disorder—Epirubicin—bone cancer	0.000141	0.00217	CcSEcCtD
Nabumetone—Anaemia—Epirubicin—bone cancer	0.00014	0.00216	CcSEcCtD
Nabumetone—Agitation—Epirubicin—bone cancer	0.000139	0.00215	CcSEcCtD
Nabumetone—Flatulence—Doxorubicin—bone cancer	0.000138	0.00213	CcSEcCtD
Nabumetone—Tension—Doxorubicin—bone cancer	0.000138	0.00212	CcSEcCtD
Nabumetone—Malaise—Epirubicin—bone cancer	0.000137	0.00211	CcSEcCtD
Nabumetone—Discomfort—Methotrexate—bone cancer	0.000136	0.0021	CcSEcCtD
Nabumetone—Nervousness—Doxorubicin—bone cancer	0.000136	0.0021	CcSEcCtD
Nabumetone—Vertigo—Epirubicin—bone cancer	0.000136	0.0021	CcSEcCtD
Nabumetone—Syncope—Epirubicin—bone cancer	0.000136	0.0021	CcSEcCtD
Nabumetone—Leukopenia—Epirubicin—bone cancer	0.000136	0.00209	CcSEcCtD
Nabumetone—Palpitations—Epirubicin—bone cancer	0.000134	0.00207	CcSEcCtD
Nabumetone—Confusional state—Methotrexate—bone cancer	0.000133	0.00206	CcSEcCtD
Nabumetone—Loss of consciousness—Epirubicin—bone cancer	0.000133	0.00206	CcSEcCtD
Nabumetone—Cough—Epirubicin—bone cancer	0.000132	0.00204	CcSEcCtD
Nabumetone—Anaphylactic shock—Methotrexate—bone cancer	0.000132	0.00204	CcSEcCtD
Nabumetone—Hypertension—Epirubicin—bone cancer	0.000131	0.00202	CcSEcCtD
Nabumetone—Ill-defined disorder—Doxorubicin—bone cancer	0.00013	0.00201	CcSEcCtD
Nabumetone—Anaemia—Doxorubicin—bone cancer	0.00013	0.002	CcSEcCtD
Nabumetone—Thrombocytopenia—Methotrexate—bone cancer	0.000129	0.002	CcSEcCtD
Nabumetone—Agitation—Doxorubicin—bone cancer	0.000129	0.00199	CcSEcCtD
Nabumetone—Anxiety—Epirubicin—bone cancer	0.000129	0.00198	CcSEcCtD
Nabumetone—Hyperhidrosis—Methotrexate—bone cancer	0.000128	0.00197	CcSEcCtD
Nabumetone—Discomfort—Epirubicin—bone cancer	0.000127	0.00197	CcSEcCtD
Nabumetone—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000127	0.0359	CbGpPWpGaD
Nabumetone—Malaise—Doxorubicin—bone cancer	0.000126	0.00195	CcSEcCtD
Nabumetone—Dry mouth—Epirubicin—bone cancer	0.000126	0.00195	CcSEcCtD
Nabumetone—Vertigo—Doxorubicin—bone cancer	0.000126	0.00194	CcSEcCtD
Nabumetone—Anorexia—Methotrexate—bone cancer	0.000126	0.00194	CcSEcCtD
Nabumetone—Syncope—Doxorubicin—bone cancer	0.000126	0.00194	CcSEcCtD
Nabumetone—Leukopenia—Doxorubicin—bone cancer	0.000125	0.00194	CcSEcCtD
Nabumetone—Confusional state—Epirubicin—bone cancer	0.000125	0.00192	CcSEcCtD
Nabumetone—Palpitations—Doxorubicin—bone cancer	0.000124	0.00191	CcSEcCtD
Nabumetone—Anaphylactic shock—Epirubicin—bone cancer	0.000124	0.00191	CcSEcCtD
Nabumetone—Oedema—Epirubicin—bone cancer	0.000124	0.00191	CcSEcCtD
Nabumetone—Loss of consciousness—Doxorubicin—bone cancer	0.000123	0.0019	CcSEcCtD
Nabumetone—Cough—Doxorubicin—bone cancer	0.000122	0.00189	CcSEcCtD
Nabumetone—Shock—Epirubicin—bone cancer	0.000122	0.00188	CcSEcCtD
Nabumetone—Thrombocytopenia—Epirubicin—bone cancer	0.000121	0.00187	CcSEcCtD
Nabumetone—Hypertension—Doxorubicin—bone cancer	0.000121	0.00187	CcSEcCtD
Nabumetone—Hyperhidrosis—Epirubicin—bone cancer	0.00012	0.00185	CcSEcCtD
Nabumetone—Insomnia—Methotrexate—bone cancer	0.000119	0.00184	CcSEcCtD
Nabumetone—Anxiety—Doxorubicin—bone cancer	0.000119	0.00184	CcSEcCtD
Nabumetone—Paraesthesia—Methotrexate—bone cancer	0.000119	0.00183	CcSEcCtD
Nabumetone—Discomfort—Doxorubicin—bone cancer	0.000118	0.00182	CcSEcCtD
Nabumetone—Anorexia—Epirubicin—bone cancer	0.000118	0.00182	CcSEcCtD
Nabumetone—Dyspnoea—Methotrexate—bone cancer	0.000118	0.00182	CcSEcCtD
Nabumetone—Somnolence—Methotrexate—bone cancer	0.000117	0.00181	CcSEcCtD
Nabumetone—Dry mouth—Doxorubicin—bone cancer	0.000117	0.0018	CcSEcCtD
Nabumetone—Dyspepsia—Methotrexate—bone cancer	0.000116	0.0018	CcSEcCtD
Nabumetone—Confusional state—Doxorubicin—bone cancer	0.000115	0.00178	CcSEcCtD
Nabumetone—Decreased appetite—Methotrexate—bone cancer	0.000115	0.00177	CcSEcCtD
Nabumetone—Anaphylactic shock—Doxorubicin—bone cancer	0.000114	0.00177	CcSEcCtD
Nabumetone—Oedema—Doxorubicin—bone cancer	0.000114	0.00177	CcSEcCtD
Nabumetone—Fatigue—Methotrexate—bone cancer	0.000114	0.00176	CcSEcCtD
Nabumetone—Shock—Doxorubicin—bone cancer	0.000113	0.00174	CcSEcCtD
Nabumetone—Thrombocytopenia—Doxorubicin—bone cancer	0.000112	0.00173	CcSEcCtD
Nabumetone—Insomnia—Epirubicin—bone cancer	0.000112	0.00173	CcSEcCtD
Nabumetone—Paraesthesia—Epirubicin—bone cancer	0.000111	0.00171	CcSEcCtD
Nabumetone—Hyperhidrosis—Doxorubicin—bone cancer	0.000111	0.00171	CcSEcCtD
Nabumetone—Dyspnoea—Epirubicin—bone cancer	0.00011	0.0017	CcSEcCtD
Nabumetone—Somnolence—Epirubicin—bone cancer	0.00011	0.0017	CcSEcCtD
Nabumetone—Anorexia—Doxorubicin—bone cancer	0.000109	0.00168	CcSEcCtD
Nabumetone—Feeling abnormal—Methotrexate—bone cancer	0.000109	0.00168	CcSEcCtD
Nabumetone—Dyspepsia—Epirubicin—bone cancer	0.000109	0.00168	CcSEcCtD
Nabumetone—Gastrointestinal pain—Methotrexate—bone cancer	0.000108	0.00167	CcSEcCtD
Nabumetone—Decreased appetite—Epirubicin—bone cancer	0.000107	0.00166	CcSEcCtD
Nabumetone—Fatigue—Epirubicin—bone cancer	0.000107	0.00165	CcSEcCtD
Nabumetone—Constipation—Epirubicin—bone cancer	0.000106	0.00163	CcSEcCtD
Nabumetone—Urticaria—Methotrexate—bone cancer	0.000105	0.00162	CcSEcCtD
Nabumetone—Abdominal pain—Methotrexate—bone cancer	0.000104	0.00161	CcSEcCtD
Nabumetone—Body temperature increased—Methotrexate—bone cancer	0.000104	0.00161	CcSEcCtD
Nabumetone—Insomnia—Doxorubicin—bone cancer	0.000103	0.0016	CcSEcCtD
Nabumetone—Paraesthesia—Doxorubicin—bone cancer	0.000103	0.00159	CcSEcCtD
Nabumetone—Dyspnoea—Doxorubicin—bone cancer	0.000102	0.00157	CcSEcCtD
Nabumetone—Feeling abnormal—Epirubicin—bone cancer	0.000102	0.00157	CcSEcCtD
Nabumetone—Somnolence—Doxorubicin—bone cancer	0.000102	0.00157	CcSEcCtD
Nabumetone—Gastrointestinal pain—Epirubicin—bone cancer	0.000101	0.00156	CcSEcCtD
Nabumetone—Dyspepsia—Doxorubicin—bone cancer	0.000101	0.00155	CcSEcCtD
Nabumetone—Decreased appetite—Doxorubicin—bone cancer	9.94e-05	0.00154	CcSEcCtD
Nabumetone—Fatigue—Doxorubicin—bone cancer	9.86e-05	0.00152	CcSEcCtD
Nabumetone—Urticaria—Epirubicin—bone cancer	9.82e-05	0.00152	CcSEcCtD
Nabumetone—Constipation—Doxorubicin—bone cancer	9.78e-05	0.00151	CcSEcCtD
Nabumetone—Body temperature increased—Epirubicin—bone cancer	9.77e-05	0.00151	CcSEcCtD
Nabumetone—Abdominal pain—Epirubicin—bone cancer	9.77e-05	0.00151	CcSEcCtD
Nabumetone—Hypersensitivity—Methotrexate—bone cancer	9.73e-05	0.0015	CcSEcCtD
Nabumetone—Asthenia—Methotrexate—bone cancer	9.48e-05	0.00146	CcSEcCtD
Nabumetone—Feeling abnormal—Doxorubicin—bone cancer	9.43e-05	0.00146	CcSEcCtD
Nabumetone—Gastrointestinal pain—Doxorubicin—bone cancer	9.35e-05	0.00144	CcSEcCtD
Nabumetone—Pruritus—Methotrexate—bone cancer	9.35e-05	0.00144	CcSEcCtD
Nabumetone—Hypersensitivity—Epirubicin—bone cancer	9.11e-05	0.00141	CcSEcCtD
Nabumetone—Urticaria—Doxorubicin—bone cancer	9.09e-05	0.0014	CcSEcCtD
Nabumetone—Abdominal pain—Doxorubicin—bone cancer	9.04e-05	0.0014	CcSEcCtD
Nabumetone—Body temperature increased—Doxorubicin—bone cancer	9.04e-05	0.0014	CcSEcCtD
Nabumetone—Diarrhoea—Methotrexate—bone cancer	9.04e-05	0.0014	CcSEcCtD
Nabumetone—Asthenia—Epirubicin—bone cancer	8.87e-05	0.00137	CcSEcCtD
Nabumetone—Pruritus—Epirubicin—bone cancer	8.75e-05	0.00135	CcSEcCtD
Nabumetone—Dizziness—Methotrexate—bone cancer	8.74e-05	0.00135	CcSEcCtD
Nabumetone—Diarrhoea—Epirubicin—bone cancer	8.46e-05	0.00131	CcSEcCtD
Nabumetone—Hypersensitivity—Doxorubicin—bone cancer	8.43e-05	0.0013	CcSEcCtD
Nabumetone—Vomiting—Methotrexate—bone cancer	8.4e-05	0.0013	CcSEcCtD
Nabumetone—Rash—Methotrexate—bone cancer	8.33e-05	0.00129	CcSEcCtD
Nabumetone—Dermatitis—Methotrexate—bone cancer	8.32e-05	0.00128	CcSEcCtD
Nabumetone—Headache—Methotrexate—bone cancer	8.28e-05	0.00128	CcSEcCtD
Nabumetone—Asthenia—Doxorubicin—bone cancer	8.21e-05	0.00127	CcSEcCtD
Nabumetone—Dizziness—Epirubicin—bone cancer	8.18e-05	0.00126	CcSEcCtD
Nabumetone—Pruritus—Doxorubicin—bone cancer	8.09e-05	0.00125	CcSEcCtD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	8.05e-05	0.0227	CbGpPWpGaD
Nabumetone—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	8.04e-05	0.0227	CbGpPWpGaD
Nabumetone—Vomiting—Epirubicin—bone cancer	7.86e-05	0.00121	CcSEcCtD
Nabumetone—Nausea—Methotrexate—bone cancer	7.85e-05	0.00121	CcSEcCtD
Nabumetone—Diarrhoea—Doxorubicin—bone cancer	7.83e-05	0.00121	CcSEcCtD
Nabumetone—Rash—Epirubicin—bone cancer	7.8e-05	0.0012	CcSEcCtD
Nabumetone—Dermatitis—Epirubicin—bone cancer	7.79e-05	0.0012	CcSEcCtD
Nabumetone—Headache—Epirubicin—bone cancer	7.75e-05	0.0012	CcSEcCtD
Nabumetone—Dizziness—Doxorubicin—bone cancer	7.57e-05	0.00117	CcSEcCtD
Nabumetone—Nausea—Epirubicin—bone cancer	7.34e-05	0.00113	CcSEcCtD
Nabumetone—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	7.33e-05	0.0207	CbGpPWpGaD
Nabumetone—Vomiting—Doxorubicin—bone cancer	7.27e-05	0.00112	CcSEcCtD
Nabumetone—Rash—Doxorubicin—bone cancer	7.21e-05	0.00111	CcSEcCtD
Nabumetone—Dermatitis—Doxorubicin—bone cancer	7.21e-05	0.00111	CcSEcCtD
Nabumetone—Headache—Doxorubicin—bone cancer	7.17e-05	0.00111	CcSEcCtD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	7.1e-05	0.0201	CbGpPWpGaD
Nabumetone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	6.86e-05	0.0194	CbGpPWpGaD
Nabumetone—Nausea—Doxorubicin—bone cancer	6.8e-05	0.00105	CcSEcCtD
Nabumetone—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	6.67e-05	0.0188	CbGpPWpGaD
Nabumetone—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	6.39e-05	0.018	CbGpPWpGaD
Nabumetone—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	6.3e-05	0.0178	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—KIT—bone cancer	6.17e-05	0.0174	CbGpPWpGaD
Nabumetone—CYP1A2—Xenobiotics—CYP3A4—bone cancer	6.13e-05	0.0173	CbGpPWpGaD
Nabumetone—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	5.89e-05	0.0167	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	5.47e-05	0.0154	CbGpPWpGaD
Nabumetone—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	5.23e-05	0.0148	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	5.2e-05	0.0147	CbGpPWpGaD
Nabumetone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	5.17e-05	0.0146	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—PTGS2—bone cancer	4.69e-05	0.0132	CbGpPWpGaD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	4.59e-05	0.013	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—PTGS2—bone cancer	4.52e-05	0.0128	CbGpPWpGaD
Nabumetone—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	4.37e-05	0.0124	CbGpPWpGaD
Nabumetone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	4.01e-05	0.0113	CbGpPWpGaD
Nabumetone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	3.94e-05	0.0111	CbGpPWpGaD
Nabumetone—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	3.46e-05	0.00977	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—TP53—bone cancer	3.38e-05	0.00956	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	3.23e-05	0.00912	CbGpPWpGaD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	3.21e-05	0.00908	CbGpPWpGaD
Nabumetone—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	3.15e-05	0.0089	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	3e-05	0.00847	CbGpPWpGaD
Nabumetone—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	2.9e-05	0.00821	CbGpPWpGaD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	2.77e-05	0.00781	CbGpPWpGaD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	2.55e-05	0.00719	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	2.53e-05	0.00714	CbGpPWpGaD
Nabumetone—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	2.51e-05	0.0071	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—CYP3A4—bone cancer	2.44e-05	0.00689	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	2.15e-05	0.00607	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—GSTP1—bone cancer	2.09e-05	0.0059	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	2.08e-05	0.00587	CbGpPWpGaD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	2.06e-05	0.00583	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—KIT—bone cancer	2.01e-05	0.00567	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	1.96e-05	0.00553	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	1.85e-05	0.00522	CbGpPWpGaD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	1.83e-05	0.00516	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	1.78e-05	0.00503	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	1.76e-05	0.00496	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	1.75e-05	0.00494	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	1.7e-05	0.0048	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CDK4—bone cancer	1.62e-05	0.00459	CbGpPWpGaD
Nabumetone—CYP1A2—Phase II conjugation—GSTP1—bone cancer	1.6e-05	0.00453	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	1.49e-05	0.00421	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NDUFA12—bone cancer	1.46e-05	0.00413	CbGpPWpGaD
Nabumetone—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	1.45e-05	0.00409	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—RB1—bone cancer	1.41e-05	0.00399	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	1.39e-05	0.00394	CbGpPWpGaD
Nabumetone—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	1.3e-05	0.00369	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	1.26e-05	0.00355	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NT5C3A—bone cancer	1.21e-05	0.00342	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NDUFA12—bone cancer	1.16e-05	0.00328	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	1.1e-05	0.00312	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—CYP3A4—bone cancer	1.1e-05	0.0031	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	1.08e-05	0.00305	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MMP9—bone cancer	1.02e-05	0.00288	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	9.89e-06	0.00279	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	9.89e-06	0.00279	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NT5C3A—bone cancer	9.62e-06	0.00272	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTP1—bone cancer	9.37e-06	0.00265	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	9.25e-06	0.00261	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—EGFR—bone cancer	8.22e-06	0.00232	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	8.19e-06	0.00231	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	7.12e-06	0.00201	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TP53—bone cancer	6.9e-06	0.00195	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NDUFA12—bone cancer	6.57e-06	0.00186	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	5.59e-06	0.00158	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NT5C3A—bone cancer	5.44e-06	0.00154	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ENO2—bone cancer	5.31e-06	0.0015	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ENO2—bone cancer	5.03e-06	0.00142	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—DHFR—bone cancer	4.92e-06	0.00139	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.7e-06	0.00133	CbGpPWpGaD
Nabumetone—PTGS2—Disease—DHFR—bone cancer	4.67e-06	0.00132	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GNA11—bone cancer	4.6e-06	0.0013	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ENO2—bone cancer	4.21e-06	0.00119	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP3A4—bone cancer	4.17e-06	0.00118	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.15e-06	0.00117	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—DHFR—bone cancer	3.91e-06	0.0011	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GNA11—bone cancer	3.65e-06	0.00103	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTP1—bone cancer	3.57e-06	0.00101	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TGFBR2—bone cancer	3.38e-06	0.000956	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP3A4—bone cancer	3.31e-06	0.000936	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTP1—bone cancer	2.83e-06	0.0008	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ENO2—bone cancer	2.38e-06	0.000674	CbGpPWpGaD
Nabumetone—PTGS2—Disease—KIT—bone cancer	2.31e-06	0.000652	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—DHFR—bone cancer	2.21e-06	0.000625	CbGpPWpGaD
Nabumetone—PTGS2—Disease—BRAF—bone cancer	2.17e-06	0.000613	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GNA11—bone cancer	2.07e-06	0.000584	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP3A4—bone cancer	1.87e-06	0.00053	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.86e-06	0.000527	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTGS2—bone cancer	1.85e-06	0.000522	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MDM2—bone cancer	1.82e-06	0.000514	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTP1—bone cancer	1.6e-06	0.000453	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EGFR—bone cancer	1.24e-06	0.000351	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTGS2—bone cancer	8.31e-07	0.000235	CbGpPWpGaD
